Top analyst Vijay Rakesh spotlights a buying opportunity thanks to robust DRAM/NAND fundamentals.
Tenapanor is a viable drug in the treatment of IBS-C, says Cantor’s Mara Goldstein.
Trevena Inc (NASDAQ:TRVN) shares are tumbling nearly 16% to $1.98 in after-hours trading Wednesday, after the biopharmaceutical company announced that the development of …
Bioblast Pharma Ltd (NASDAQ:ORPN) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 54% …
No surprises within Rhopressa briefing documents – Good news for Aerie investors.
Celsion Corporation (NASDAQ:CLSN) shareholders are stoked in anticipation for tomorrow’s R&D Day conference set in New York City, with shares experiencing a just …
A heavy-hitter catalyst is about to go up to bat for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with a key FDA decision looming in the foreground, …
Helios and Matheson Analytics Inc (NASDAQ:HMNY) investors are deciding they want to play with fire, or at least that is how infamous short-seller …
William Blair likes NTNX’s value-added reseller buzz on demand; Jefferies spotlights software advantage.
Dewey Steadman believes Aerie’s Rhopressa is in good standing for Friday’s AdCom.
